Publications by authors named "Emel Serap Monkul Nery"

Article Synopsis
  • The study aimed to evaluate the effectiveness and side effects of donanemab, an antibody targeting amyloid plaques in the brains of Alzheimer's patients, as current treatment options are limited.
  • The research involved a large-scale, 18-month clinical trial with 1736 participants diagnosed with early symptomatic Alzheimer disease, conducted across 277 medical centers in 8 countries from June 2020 to April 2023.
  • Results showed that out of 24 assessed outcomes, 23 indicated significant improvement, with the donanemab group demonstrating a notable decrease in cognitive impairment compared to the placebo group over the 76-week period.
View Article and Find Full Text PDF

Introduction: Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to < 18 years.

Methods: Cohort 1 (15 to ≤ 40 kg) and Cohort 2 (> 40 to ≤ 55 kg) received single oral doses of lasmiditan (100 mg and 200 mg, respectively).

View Article and Find Full Text PDF

Objective: The purpose of this study was to assess the long-term safety and tolerability of edivoxetine, a selective norepinephrine reuptake inhibitor, which was being developed as monotherapy in pediatric attention-deficit/hyperactivity disorder (ADHD).

Methods: This was an open-label study of edivoxetine once daily dosing (0.1-0.

View Article and Find Full Text PDF